Literature DB >> 7009135

Fenbufen: a review of its pharmacological properties and therapeutic use in rheumatic diseases and acute pain.

R N Brogden, R C Heel, T M Speight, G S Avery.   

Abstract

Fenbufen is a phenylalkanoic acid derivative with analgesic and anti-inflammatory activity. The anti-inflammatory activity appears to reside in the metabolites. Published data indicate that fenbufen 600 to 1000mg daily is comparable in effectiveness to therapeutic doses (3 to 4g) of aspirin, indomethacin (75 to 100mg) or phenylbutazone (300 to 400mg) in rheumatoid arthritis, but generally causes fewer side effects. At a daily dosage of 600mg, fenbufen is comparable with aspirin 3.6g or indomethacin 75mg in osteoarthritis. Initial studies suggest that fenbufen 600 to 900mg daily is at least as effective as ibuprofen 1200 to 1800mg of fenoprofen 1800 to 2400mg daily. It has not been compared with naproxen or sulindac in adequate numbers of patients. Fenbufen is effective when given twice daily and there is some evidence that once daily dosage is adequate in known responders to the drug. As with other non-steroidal alkanoic acid drugs, gastrointestinal complaints are the most frequently reported side effects, but there have been no reports of peptic ulcer to date.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7009135     DOI: 10.2165/00003495-198121010-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  31 in total

1.  Alclofenac: a review of its pharmacological properties and therapeutic efficacy in rheumatoid arthritis and allied rheumatic disorders.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-10       Impact factor: 9.546

Review 2.  Sulindac: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-08       Impact factor: 9.546

3.  Fenbufen--a new nonsteroidal anti-inflammatory agent: comparison with phenylbutazone in rheumatoid arthritis.

Authors:  I De Salcedo
Journal:  Curr Ther Res Clin Exp       Date:  1975-08

4.  [Clinical trial of a new anti-inflammatory agent in rheumatoid arthritis].

Authors:  R Soldati; G Sorbilli; P Di Benedetto
Journal:  Clin Ter       Date:  1978-02-28

5.  Pharmacokinetics of fenbufen in man.

Authors:  G Cuisinaud; J Legheand; G Llorca; C Belkahia; E Lejeune; J Sassard
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

6.  A comparative clinical trial of fenbufen and indomethacin in patients with rheumatoid arthritis.

Authors:  J M Vergara-Castro; L F Arias; B P Greenberg
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

Review 7.  A review of the effects of fenbufen and a metabolite, biphenylacetic acid, on platelet biochemistry and function.

Authors:  C Kohler; E Tolman; W Wooding; L Ellenbogen
Journal:  Arzneimittelforschung       Date:  1980

Review 8.  Diflunisal: a review of its pharmacological properties and therapeutic use in pain and musculoskeletal strains and sprains and pain in osteoarthritis.

Authors:  R N Brogden; R C Heel; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-02       Impact factor: 9.546

9.  Fenbufen, a new non-steroidal anti-inflammatory agent in rheumatoid arthritis, its efficacy and toxicity.

Authors:  A Becker; R T Hoffmeister
Journal:  J Int Med Res       Date:  1980       Impact factor: 1.671

10.  Disposition and metabolism of fenbufen in several laboratory animals.

Authors:  F S Chiccarelli; H J Eisner; G E Van Lear
Journal:  Arzneimittelforschung       Date:  1980
View more
  11 in total

1.  Comparative bioavailability of two different rectal preparations of piroxicam in man.

Authors:  S Benkö; G Grézal; E Nagy; I Klebovich
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Carrier-linked mutual prodrugs of biphenylacetic acid as a promising alternative to bioprecursor fenbufen: design, kinetics, and pharmacological studies.

Authors:  Suneela Dhaneshwar; Manisha Kusurkar; Subhash Bodhankar; Gopal Bihani
Journal:  Inflammopharmacology       Date:  2013-11-01       Impact factor: 4.473

Review 3.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

4.  Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design.

Authors:  Min Wu; Cuiyun Li; Hong Zhang; Jixuan Sun; Xiaoxue Zhu; Xiaojiao Li; Xuedong Gao; Wei Wang; Yanhua Ding
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

Review 5.  Single dose oral fenoprofen for acute postoperative pain in adults.

Authors:  Maria X Traa; Sheena Derry; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

Review 6.  Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

Review 7.  Acute poisoning due to non-steroidal anti-inflammatory drugs. Clinical features and management.

Authors:  J A Vale; T J Meredith
Journal:  Med Toxicol       Date:  1986 Jan-Feb

Review 8.  Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs). Recognition, management and avoidance.

Authors:  A G Johnson; P Seideman; R O Day
Journal:  Drug Saf       Date:  1993-02       Impact factor: 5.606

Review 9.  Single dose oral fenbufen for acute postoperative pain in adults.

Authors:  R Andrew Moore; Sheena Derry; Henry J McQuay
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

Review 10.  Piroxicam: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.